QDEL (QuidelOrtho) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $724 million, a 2% increase year-over-year (YoY); 7% growth excluding COVID and Donor Screening revenues.

Full Year Revenue: $2.73 billion, meeting 2025 guidance; Non-respiratory revenue grew 5%.

Labs Business: Grew 7% in Q4 and 6% for the full year, accounting for 55% of total revenue.

Respiratory Revenue: Declined 14% in Q4 and 20% for the full year due to decreased COVID testing.

Adjusted EBITDA: $153 million in Q4 with a margin of 21%; full year adjusted EBITDA was $597 million, a 22% margin (up 240 basis points YoY).

Adjusted EPS: $0.46 for Q4 and $2.12 for the full year, reflecting a 15% growth YoY.

Free Cash Flow: $87 million in Q4; full year free cash flow was $77 million, with recurring cash flow at $100 million (17% of adjusted EBITDA).

2Strategic Updates and Business Highlights

Cost Savings Initiatives: Achieved $140 million in cost savings, improving operational efficiency and financial flexibility.

Leadership Changes: CFO Joe Busky announced retirement effective June 2026; succession planning is underway.

R&D Progress: FDA clearances for new assays, including a high-sensitivity troponin assay and an ID MTS Direct Antiglobulin Test Card, enhancing product offerings.

Product Pipeline: Upcoming launches in 2026 include the VITROS 450 platform and new immunoassay platforms for international markets.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected between $2.7 billion and $2.9 billion; Labs business projected to grow mid-single digits.

Adjusted EBITDA Guidance: Anticipated between $630 million and $670 million, with a margin of approximately 23.3%.

Free Cash Flow Guidance: Projected between $120 million and $160 million, with a focus on improving cash flow conversion.

EPS Guidance: Adjusted diluted EPS expected between $2.00 and $2.42.

4Challenges and Points of Concern

Respiratory Revenue Decline: Significant drop in COVID-related revenue impacts overall growth.

Cash Flow Conversion: Actual cash flow fell short of targets due to timing issues; 2026 cash flow conversion goal set at 30%, below the long-term target of 50%.

Goodwill Impairment: A significant non-cash goodwill charge of $701 million recorded in Q3 2025, affecting GAAP results but not operational cash flow.

Market Uncertainty: Potential impact from China's value-based procurement program for dry chemistry test strips, which could affect revenue if QuidelOrtho products are included.

5Notable Q&A Insights

Free Cash Flow Timing: CFO Joe Busky clarified that $40 million in expected cash flow slipped from Q4 2025 to January 2026, which affected the cash flow conversion rate.

Lab Growth Sustainability: Management expressed confidence in the sustainability of growth rates, citing strong market positions and opportunities in immunoassay.

China Market: No new developments on the value-based procurement program; potential revenue impact estimated at 0.5% to 1% of total revenue.

Future Margin Improvement: Management aims for gross margins to approach 50% over the next few years, driven by direct procurement initiatives and improved product mix. This summary encapsulates the key financial metrics, strategic initiatives, forward-looking guidance, and challenges faced by QuidelOrtho, providing a comprehensive overview of the company's performance and outlook.